middl
east
respiratori
syndrom
coronaviru
merscov
highli
pathogen
respiratori
viru
mechan
may
driven
innat
immun
respons
despit
effort
scientif
studi
relat
viru
middl
east
respiratori
syndrom
mer
still
public
health
concern
merscov
infect
high
mortal
rate
date
therapeut
vaccin
discov
effect
treat
prevent
diseas
review
summar
understand
molecular
biolog
event
compound
act
merscov
inhibitor
outcom
exist
therapeut
option
variou
drug
undergo
clinic
trial
current
sever
therapeut
option
employ
convalesc
plasma
cp
intraven
immunoglobulin
ivig
monoclon
antibodi
repurpos
exist
clinic
approv
drug
howev
therapeut
option
drawback
thu
need
altern
approach
requir
effect
therapeut
treatment
brought
necess
addit
mer
treatment
suggest
antimicrobi
peptid
amp
may
use
altern
therapeut
agent
merscov
infect
addit
propos
feasibl
develop
effect
agent
repurpos
exist
clinic
approv
anticoronaviru
antivir
peptid
drug
middl
east
respiratori
syndrom
mer
respiratori
diseas
caus
mer
coronaviru
merscov
merscov
first
report
saudi
arabia
spread
countri
mostli
arabian
peninsula
unit
arab
emir
qatar
oman
jordan
kuwait
yemen
lebanon
march
world
health
organ
report
confirm
mer
case
includ
death
countri
mer
spread
among
peopl
caus
sever
complic
lead
death
henc
need
develop
effect
therapeut
prophylact
agent
prevent
treatment
shown
hospit
outbreak
mer
due
humantohuman
transmiss
current
regist
treatment
vaccin
diseas
merscov
infect
rather
manag
drug
treatment
regim
addit
prevent
measur
infect
reinfect
sever
studi
demonstr
varieti
therapeut
inhibit
merscov
replic
cell
cultur
review
summar
import
merscov
drug
target
ii
present
therapeut
option
avail
mer
describ
efficaci
iii
discuss
role
peptid
research
virolog
import
antimicrobi
peptid
amp
potenti
therapeut
option
mer
rapid
develop
comput
biolog
approach
envisag
novel
effect
mer
therapi
could
develop
use
amp
human
coronavirus
broadli
classifi
either
alphacoronaviru
betacoronaviru
merscov
belong
betacoronaviru
famili
causal
transmiss
pathway
merscov
demonstr
may
origin
bat
dromedari
camel
serv
intermedi
host
human
infect
merscov
shown
modul
innat
immun
respons
antigen
present
mitogenactiv
protein
kinas
mapk
apoptot
pathway
structur
merscov
consist
four
structur
protein
shown
fig
includ
spike
protein
envelop
e
protein
membran
protein
nucleocapsid
n
protein
protein
type
transmembran
glycoprotein
locat
viral
envelop
surfac
trimer
state
consist
subunit
play
role
viral
entri
bind
fusion
subunit
receptorbind
domain
rbd
fig
rbd
respons
bind
cellular
receptor
dipeptidyl
peptidas
subunit
involv
two
region
name
heptad
repeat
fig
assembl
complex
call
fusion
core
repres
key
membran
fusion
architectur
e
protein
present
mainli
intracellular
membran
viru
play
major
role
viral
assembl
bud
intracellular
traffick
surya
et
al
report
coronaviru
e
protein
amino
acid
long
predict
least
one
transmembran
later
found
e
protein
total
length
amino
acid
residu
protein
compon
viral
envelop
play
role
viru
morphogenesi
assembl
via
interact
viral
protein
e
protein
insert
membran
rough
endoplasm
reticulum
get
transport
vicin
endoplasm
reticulumgolgi
area
interact
n
protein
form
particl
interact
eventu
interfer
fusion
cellular
viral
membran
thu
develop
fusion
peptid
great
import
peptidebas
therapeut
option
addit
merscov
compris
two
larg
polyprotein
name
polyprotein
cleav
nonstructur
protein
nsp
two
proteas
papainlik
proteas
plpro
proteas
respons
process
nsp
requir
replic
transcript
plpro
respons
cleavag
posit
develop
three
nsp
wherea
cleav
remain
posit
nsp
respons
viral
rnadepend
rna
polymeras
activ
primas
activ
rna
helicas
activ
exoribonucleas
activ
endoribonucleas
activ
omethyltransferas
activ
omethyltransferas
activ
stimul
act
alloster
activ
studi
reveal
coronaviru
nsp
could
use
drug
target
develop
new
therapi
fig
show
proteas
bound
design
inhibitor
structur
nonstructur
protein
act
therapeut
target
variou
therapeut
option
implement
discuss
sectionsvari
therapeut
agent
merscov
action
peptid
antivir
activ
variou
coronavirus
sever
way
inhibit
spread
merscov
repurpos
clinic
develop
drug
ii
use
convalesc
plasma
cp
whole
blood
therapi
iii
intraven
immunoglobulin
ivig
iv
monoclon
antibodi
v
therapeut
discuss
follow
subsect
repurpos
method
target
exist
drug
molecul
treat
new
diseas
repurpos
viabl
target
profil
develop
drug
receptor
molecul
screen
compound
differ
molecul
librari
occur
repurpos
becom
possibl
faster
pace
latest
develop
comput
biolog
ration
design
develop
novel
approv
agent
potent
antivir
activ
repurpos
exist
clinic
fda
approv
drug
use
target
viral
entri
high
throughput
screen
compound
small
molecul
help
research
evalu
larg
librari
drug
vitro
antivir
activ
novel
target
advantag
repurpos
method
save
time
ii
lower
cost
develop
new
drug
repurpos
drug
may
potenti
antivir
effect
merscov
exampl
repurpos
drug
shown
anti
b
show
spike
protein
subunit
form
fusion
core
sp
signal
peptid
fp
fusion
peptid
heptad
repeat
tm
transmembran
domain
cp
cytoplasm
domain
c
show
linker
show
merscov
structur
complex
human
pdb
id
visualis
biovia
ds
visual
e
show
structur
merscov
proteas
bound
design
inhibitor
pdb
id
visualis
biovia
ds
visual
coronaviru
valid
activ
includ
ribavirin
hexachloropen
nitazoxanid
homoharringtonin
ribavirin
report
antimerscov
activ
advers
side
effect
occurr
hemolysi
nitazoxanid
shown
vitro
activ
merscov
coronaviru
infect
inhibit
express
viral
nucleocapsid
protein
vitro
studi
show
cyclosporin
inhibit
merscov
human
monkey
cell
line
recent
studi
shihchao
et
al
test
antivir
activ
resveratrol
phytocompound
grape
seed
red
wine
show
resveratrol
could
significantli
inhibit
merscov
nucleocapsid
express
exampl
use
small
molecul
therapeut
option
merscov
given
tabl
variou
studi
repurpos
drug
employ
hybrid
two
drug
exampl
wild
et
al
employ
alisporivir
inhibit
replic
merscov
sarscov
howev
found
alisporivir
combin
ribavirin
enhanc
antivir
efficaci
alisporivir
done
use
cellcultur
base
screen
anoth
studi
show
combin
lopinavirritonavir
found
effect
marmoset
infect
merscov
interferon
shown
potent
inhibitor
merscov
replic
howev
combin
interferonalpha
ribavirin
drug
routin
use
treat
hepat
c
reduc
merscov
replic
administ
rhesu
macaqu
addit
ribavirin
administ
patient
sever
merscov
infect
surviv
improv
anoth
case
report
lopinavirritonavirbas
combin
antivir
therapi
use
merscov
infect
south
korea
tawalah
et
al
evalu
virolog
clinic
progress
respons
lopinavirritonavir
administ
differ
treatment
option
mer
patient
studi
suggest
effect
therapeut
regimen
low
dose
ribavirinpegyl
interferon
combin
sever
studi
shown
effect
ribavirin
coupl
interferon
mycophenol
acid
immunosuppress
drug
togeth
found
strong
inhibitori
action
merscov
combin
mycophenol
acid
lower
ec
use
convalesc
plasma
cp
whole
blood
therapi
suggest
potenti
treatment
infecti
diseas
mer
ebola
sar
cp
use
whole
blood
plasma
collect
patient
recov
viral
diseas
use
treatment
outbreak
cp
therapeut
administ
specif
vaccin
drug
avail
treat
diseas
arabi
et
al
analys
feasibl
cp
therapi
well
safeti
clinic
laboratori
effect
critic
ill
patient
merscov
infect
suggest
cp
neutral
antibodi
immunotherapeut
hyperimmun
immunoglobulin
monoclon
antibodi
potenti
treatment
merscov
infect
howev
studi
note
largescal
screen
would
requir
limit
avail
elig
potenti
donor
suffici
level
antibodi
one
drawback
cp
unavail
lack
evid
prove
safeti
efficaci
intraven
immunoglobulin
ivig
blood
product
prepar
serum
gener
use
treat
number
autoimmun
inflammatori
condit
administr
ivig
well
studi
variou
diseas
includ
heart
failur
mycobacteri
infect
epilepsi
alzheim
etc
treatment
antibodi
administ
intraven
may
lead
renal
failur
thrombosi
mer
patient
howev
evid
ivig
antim
activ
luke
et
al
report
studi
transchromosom
tc
bovin
produc
human
polyclon
immunoglobulin
g
antibodi
neutral
merscov
vitro
assay
anim
model
implic
studi
show
potenti
offer
method
manufactur
therapeut
immunoglobulin
prevent
andor
treat
merscov
infect
andor
new
infecti
diseas
monoclon
antibodi
mab
use
clinic
diagnos
variou
diseas
sever
year
consid
potenti
method
intervent
monoclon
polyclon
antibodi
report
inhibit
merscov
infect
primari
human
bronchial
epithelia
cell
cell
antibodi
develop
use
cell
clone
technolog
immort
b
cell
human
donor
recov
mer
consid
treatment
option
sever
merscov
infect
recent
studi
identifi
character
set
seven
human
neutral
ab
nab
two
monoclon
antibodi
mab
name
agent
rbd
specif
potent
inhibitor
show
strong
neutral
activ
merscov
anoth
studi
succeed
develop
two
potenti
antibodi
proven
effect
anim
model
merscov
infect
mab
shown
activ
merscov
includ
ii
iii
iv
v
h
despit
util
product
monoclon
antibodi
time
consum
difficult
therapeut
block
merscov
smediat
cell
entri
viru
cell
membran
fusion
includ
cathespin
inhibitor
inhibitor
furin
inhibitor
kinas
inhibitor
ifitm
protein
studi
china
use
high
flow
nasal
cannula
hfnc
treat
patient
mer
summari
therapeut
option
name
repurpos
clinic
develop
drug
cp
whole
blood
therapi
ivig
use
monoclon
antibodi
advantag
disadvantag
term
gener
cost
overal
applic
led
interest
peptid
altern
therapeut
option
discuss
come
section
interest
peptid
therapeut
mimet
potenti
antagonist
variou
pathogen
peptid
research
import
aspect
pharmaceut
research
approxim
peptid
therapeut
current
evalu
clinic
trial
reason
use
peptid
inhibit
proteinprotein
interact
ii
use
altern
diseas
difficult
target
iii
advanc
tech
niqu
improv
peptid
halflif
iv
shorter
market
time
peptid
drug
littl
side
effect
littl
drug
toler
compar
chemic
drug
meanwhil
specif
treatment
high
peptid
drug
need
special
storag
condit
otherwis
protein
function
becom
inact
caus
low
oral
bioavail
propens
rapidli
metabol
mani
peptid
inhibitor
shown
activ
virus
instanc
peptid
deriv
membran
proxim
stem
region
rvfv
glycoprotein
gc
prevent
viral
fusion
rift
valley
fever
viru
peptid
specif
rift
valley
fever
viru
close
relat
variant
also
show
activ
unrel
virus
ebov
vsv
scorpion
venom
peptid
deriv
identifi
potenti
peptid
show
low
cytotox
effect
biolog
assay
lack
effect
treatment
encourag
develop
addit
therapeut
agent
increas
efficaci
overcom
advers
side
effect
occur
current
mer
treatment
grow
interest
field
peptid
therapeut
last
decad
due
numer
advers
effect
chemic
base
drug
amp
excel
candid
novel
therapeut
agent
sinc
report
possess
anticoronaviru
activ
amp
compon
first
line
defenc
immun
system
produc
eukaryot
prokaryot
speci
small
posit
charg
gene
encod
peptid
select
toxic
toward
gramposit
gramneg
bacteria
protozoa
fungi
virus
select
toxic
due
fact
microb
membran
bilay
rich
lipopolysaccharid
lp
lipoteicho
acid
lpa
thu
neg
charg
contrast
posit
charg
amp
antivir
amp
sever
mode
action
includ
block
viral
entri
heparan
sulphat
interact
inhibit
viral
entri
fuse
specif
cellular
receptor
stop
viral
fusion
interact
glycoprotein
membran
envelop
viru
variou
antivir
mechan
action
antimicrobi
peptid
includ
direct
interact
virolysi
ii
blockag
host
cell
surfac
receptor
iii
inhibit
viral
fusion
host
cell
iv
inhibit
viral
replic
v
activ
adapt
immun
respons
life
cycl
coronaviru
begin
fuse
spike
protein
host
receptor
ii
viral
entri
host
cell
iii
intracellular
viral
replic
transcript
iv
protein
product
assembl
releas
new
viru
particl
therefor
therapeut
strategi
focu
four
import
process
main
mechan
action
antivir
peptid
categor
gener
three
major
group
peptid
inhibit
fusion
peptid
inhibit
viru
entri
peptid
inhibit
replic
peptid
inhibit
assembl
releas
viru
coronavirus
enter
target
cell
induc
fusion
viral
cellular
membran
process
mediat
viral
spike
glycoprotein
subunit
protein
facilit
receptor
bind
wherea
subunit
respons
drive
viral
target
cell
membran
fusion
variou
approach
creat
peptidebas
therapeut
includ
peptid
interrupt
rbd
interact
peptid
block
interact
form
fusionact
core
peptid
interfer
cleavag
protein
strategi
employ
inhibit
fusion
protein
either
deriv
peptid
region
deriv
peptid
antimicrobi
peptid
note
peptid
deriv
either
protein
antimicrobi
peptid
antivir
compound
differ
peptid
deriv
antimicrobi
peptid
broad
spectrum
may
role
immunomodulatori
activ
deriv
organ
viru
describ
follow
peptid
deriv
rbd
subunit
spike
protein
fusion
inhibit
peptid
deriv
protein
shown
tabl
exampl
lu
et
al
design
two
synthet
peptid
amino
acid
residu
span
domain
form
stabl
sixhel
bundl
fusion
core
structur
structur
ensur
fusion
viral
envelop
host
cell
membran
two
peptid
inhibit
merscov
replic
spike
proteinmedi
cellcel
fusion
previou
studi
show
deriv
five
region
span
length
subunit
sarscov
murin
hepat
viru
mhv
studi
three
peptid
sar
wwiii
sar
wwiv
mhv
wwiv
exhibit
antivir
activ
greater
peptid
studi
inhibitori
concentr
ic
valu
rang
b
peptid
deriv
antimicrobi
peptid
peptid
deriv
antimicrobi
peptid
either
truncat
fragment
origin
peptid
replac
certain
residu
amp
anoth
residu
instanc
replac
lysin
arginin
deriv
peptid
shown
activ
variou
microorgan
instanc
antivir
activ
peptid
deriv
mous
test
one
exhibit
potent
broad
spectrum
antivir
effect
multipl
respiratori
virus
vitro
vivo
includ
influenza
viru
sarscov
merscov
entri
replic
process
coronavirus
infect
host
commenc
glycoprotein
locat
surfac
coronaviru
virion
fuse
receptor
facilit
viral
entri
host
chain
event
lead
releas
viral
genom
rna
host
cytoplasm
replic
viral
rna
final
releas
viral
particl
sever
studi
employ
inhibit
viral
entri
replic
shown
tabl
b
c
peptid
classifi
major
subgroup
peptid
deriv
subunit
spike
protein
peptid
deriv
domain
shown
activ
merscov
inhibit
viral
replic
hfl
cell
b
peptid
deriv
antimicrobi
peptid
mutant
peptid
deriv
mucropin
amp
glycin
prolin
residu
mucropin
substitut
lysin
arginin
respect
mutant
shown
activ
sarscov
inhibit
viral
replic
c
peptid
deriv
nonstructur
protein
nsp
two
peptid
deriv
nonstructur
protein
sarscov
two
peptid
inhibit
replic
sarscov
inhibitori
concentr
though
much
known
assembl
releas
process
enzym
involv
assembl
releas
process
inhibit
assembl
releas
viru
could
good
futur
target
exampl
anticoronaviru
peptid
sarscov
tgev
mhv
provid
antivir
peptid
databas
avpdb
databas
consist
variou
anticoronaviru
peptid
numer
mechan
action
sarscov
tgev
mhv
employ
potenti
therapeut
option
merscov
coronavirus
share
similar
structur
mechan
action
understand
peptid
research
suggest
peptid
may
capac
lead
molecul
potenti
drug
mer
advantag
peptid
repurpos
lead
identif
peptidebas
therapeut
treatment
mer
potenti
wider
util
therapeut
use
treatment
infect
caus
differ
human
coronavirus
furthermor
help
maintain
qualiti
reduc
cost
new
medicin
develop
urgent
need
develop
effect
mer
therapi
develop
protocol
use
randomizedcontrol
trial
studi
shown
peptid
evolv
highli
potent
signal
transduct
agent
viral
diseas
suggest
amp
success
therapeut
option
emerg
mer
pathogen
comput
biolog
coupl
virolog
acceler
advanc
design
develop
peptid
therapeut
merscov
greater
efficaci
addit
studi
suggest
repurpos
exist
clinic
approv
anticoronaviru
antivir
peptid
drug
may
use
promis
lead
develop
new
antimerscov
agent
work
support
king
abdullah
intern
medic
research
center
grant
none
declar
requir
